白宫官员：如果药品行业未取得充分进展，卫生部长将通过制定规则实施最惠国定价。 ...

【导读】医药板块，突传利空 大家好，特朗普突然对医药出手了！ 特朗普计划降低美国药品价格，医药股暴跌 5月12日，虽然市场整体大涨，但创新药板块却逆市大跌。 | 代码 | 名称 . | 涨幅%1 | 现价 | | | --- | --- | --- | --- | --- | | 688062 | 迈威生物-U K -10.96 | | 17.80 | | | 688532 | 自济神州-U K -9.04 | | 221.50 | | | e8826e | 淺環制药-U K | -1.81 | 91.73 | | | 688192 | 迪哲医药-U K | -7.36 | 52.23 | | | 300204 | 舒泰神 | -6.36 | 10.31 | | | 688206 | 百利天恒 ાર | -6.08 | 262.99 | | | 002294 | 信立泰 R | -5.75 | 38'22 | | | 002675 | 东诚药业 R | -5.60 | 13.99 | | | 688068 | 热景生物 ાર | -5.39 | 103.50 | | | 688382 | 益方生物-U K | ...

这是美国总统特朗普宣布所谓"对等关税"以来首个和美国达成协议的国家。 市场上，美股三大股指集体上涨，截至发稿，道指涨0.56%，标普500指数上涨0.58%，纳指上涨 0.82%；英国富时100指数下跌0.35%。 特朗普宣称达成首个贸易协议 当天稍早时候，特朗普在社交媒体上发布消息称："对于美国和英国来说，这应该是一个非常重要和令 人兴奋的日子。上午10时（北京时间22时），白宫椭圆形办公室举行新闻发布会。" 深夜重磅！ 据央视新闻消息，当地时间8日，英国和美国已经就关税贸易协议条款达成一致。英国政府同意进口美 国食品和农业产品方面作出让步，以换取美方降低对英国汽车出口的关税。 唐宁街并未否认该协议最早可能在本周签署的报道，尽管政府消息人士称，特朗普最近宣布对电影业征 收关税已被证明是一个重大挫折。 一位了解谈判情况的人士表示："我们现在有一个高级团队在当地，他们本周或许能够达成一些协议。 但现实是，特朗普政府一直在改变目标，就像他本周宣布的电影关税政策那样。" 此前一天，特朗普在社交平台发文称，美国东部时间周四上午10时（北京时间5月8日22时）将举行重大 新闻发布会，内容涉及与某国代表达成的一项重大贸易 ...

Group 1 - India has proposed a "zero-for-zero" tariff arrangement for specific goods, including steel, auto parts, and pharmaceuticals, during trade negotiations with the US, based on reciprocity and limited to a certain quantity of imports [1][2] - The US has expressed concerns regarding India's quality control regulations, viewing them as non-tariff trade barriers that restrict market access for American companies [1][2] - India's exports of pharmaceuticals to the US are valued at $10.5 billion, while engineering products exports amount to $19.1 billion in the new fiscal year [1] Group 2 - The proposal for "zero-for-zero" tariffs has garnered attention, but it is unlikely to be adopted due to differing economic development levels between the US and India [2] - The number of quality control orders in India has increased significantly from 14 before 2014 to over 140 since 2017, raising transparency and fairness concerns [2] - President Trump claimed that India agreed to reduce tariffs on US imports to "zero," although India has not officially confirmed this statement as negotiations are ongoing [3]

Core Viewpoint - The resurgence of "America First" is prompting the EU to enter an era of "strategic awakening," with the negative impact of U.S. tariffs on the EU economy likely to manifest sooner than the positive effects of fiscal expansion, which may only begin to outweigh the negative impacts by Q4 of this year [1][4][13]. Group 1: Strategic Awakening in the EU - The unilateralism of the Trump administration is increasing anxiety among European nations, leading to a consensus on increasing defense spending within the EU [2][13]. - Germany's €1 trillion fiscal expansion plan has completed the legislative process and will be discussed after the new government is formed [2][13]. - The EU's €800 billion proposal for "rearming Europe" is actively progressing, with national exception clause applications approved in July [2][4]. Group 2: Impact of Tariffs on the EU Economy - The static assessment indicates that U.S. tariffs will raise the effective tariff rate on imports from the EU by 9.6 percentage points, potentially reducing EU exports by approximately 1.9% and impacting EU GDP by about 0.5% [4][12]. - The pharmaceutical and organic chemical sectors are particularly vulnerable to these tariffs, with countries like Ireland, Finland, Italy, and Germany being sensitive to U.S. tariff policies [4][10]. Group 3: Fiscal Expansion and Economic Growth - Increased fiscal spending on defense and infrastructure is expected to effectively boost economic growth in Europe, with France and Germany likely to be the primary beneficiaries [4][18]. - The positive impact of fiscal expansion may take longer to materialize compared to the immediate negative effects of tariffs, with expectations that the latter will begin to diminish by Q4 of this year [4][12]. Group 4: Investment Strategies and Market Sentiment - Investor sentiment is crucial for the EU economy to avoid recession, with many European companies focusing on equipment upgrades and product R&D rather than capacity expansion [18]. - Chinese companies are encouraged to leverage the EU's fiscal expansion to accelerate strategic transformations and seek potential opportunities in Europe, particularly in sectors like electrical and optical equipment [18].

Group 1: Trade Negotiations - The U.S. has refused to grant Japan a full exemption from "reciprocal tariffs" during recent trade negotiations, with only a consideration to lower specific tariffs by 14% [1][3] - India has proposed zero tariffs on certain quantities of steel, auto parts, and pharmaceuticals in trade talks with the U.S., aiming to expedite a bilateral trade agreement expected to be reached by fall [1][3] Group 2: Economic Data - The ISM reported that the U.S. services PMI for April was 51.6, indicating a return to expansion and significantly above the expected 50.2, following a previous value of 50.8 [5][6] - In April, 11 industries reported growth, with hospitality, wholesale trade, mining, and real estate performing the best, while 6 industries contracted [6] Group 3: Market Reactions - Following the positive services data, U.S. stock indices narrowed their losses, with the Dow Jones Industrial Average rising by 0.14% and the Nasdaq's decline reducing to 0.45% [8][9] - U.S. Treasury yields increased, with the 10-year yield rising close to 4.35% and the 2-year yield reaching a daily high of 3.8467% [9][10] Group 4: Inflation and Employment Indicators - The services employment index for April was recorded at 49, indicating a slowdown in employment but an improvement from the previous value of 46.2 [7] - The services price index reached 65.1, significantly above the expected 61.4, indicating rising inflationary pressures due to tariffs [6][7]

Core Viewpoint - The implementation plan for the reform of drug, medical device, and cosmetic regulation in Hainan aims to enhance the competitiveness of the biopharmaceutical industry by introducing 20 reform measures across five key areas [1][2] Group 1: Regulatory Reforms - The plan emphasizes improving the efficiency of review and approval processes, focusing on the actual needs of enterprises during product development and registration [1] - It aims to facilitate the market entry of innovative products, targeting the launch of at least one innovative product annually and the introduction of over 60 licensed medical devices each year [1] Group 2: Innovation in Biopharmaceuticals - The initiative seeks to address bottlenecks in innovation by enhancing clinical research levels and increasing support for traditional Chinese medicine research and development [2] - By the end of 2027, the goal is to promote the registration or filing of over 15 hospital preparations [2] Group 3: International Competitiveness - The plan includes regulatory innovations to enhance product participation in international markets, aiming to create a high ground for real-world research applications [2] - It promotes the "Research and Use + Haikou/Qionghai Production" model to facilitate local production of more innovative drugs and medical devices [2] Group 4: Industry Development - The implementation of the plan is expected to significantly promote structural adjustments, efficiency transformations, and quality improvements in Hainan's biopharmaceutical industry [2] - It aims to create a unique competitive advantage for Hainan's biopharmaceutical sector, contributing to the establishment of a modern industrial system with Hainan characteristics [2]

4月22日晚间，冠昊生物（300238）(300238.SZ)披露2024年年度报告及2025年一季报。在行业变革等因 素影响下，2024年公司收入利润同比小幅下滑，营业收入实现3.77亿元，归母净利润2741.69万元。至 2025年一季度，公司收入利润恢复正增长，营业收入同比增长3.67%，实现9479.71万元，归母净利润同 比增长3.30%，实现1486.61万元，经营状况有所改善。 更值得一提的是公司在干细胞领域的布局。近年来，细胞行业在全球范围内持续蓬勃发展，展现出巨大 的潜力与活力。国内方面，尤其在2024年，国家药监局药审中心相继发布多项文件，如《免疫细胞治疗 产品临床试验技术指导原则(试行)》《人源干细胞产品药学研究与评价技术指导原则(试行)》等，从监 管政策层面为细胞治疗产业化明晰方向，规范细胞产品的药学研发与临床试验流程。政策环境的优化， 为细胞创新技术和产品的转化落地创造了有利条件。 此外，年报披露，公司在研的生物人工肝项目，目前正推进细胞药物的药学研究和体外支持装置等第三 类医疗器械性能研究工作，公司正积极与相关医院等多方合作申请开展临床前研究。若相关研发后续顺 利实现商业化，或将为 ...

Macro Economic Indicators - In Q1 2025, China's total goods trade value reached 10.3 trillion yuan, a historical high for the same period, with a year-on-year growth of 1.3%[1] - Exports amounted to 6.13 trillion yuan, increasing by 6.9%, while imports were 4.17 trillion yuan, showing a decline of 6%[1] - Monthly trade growth showed a recovery trend, with March exports growing by 6% after a decline of 2.2% in January and stability in February[1] U.S. Policy and Market Reactions - The U.S. government initiated a national security investigation into semiconductor and pharmaceutical imports, potentially leading to tariffs[1] - The U.S. President is expected to announce semiconductor tariff rates this week, while the Treasury Secretary indicated no evidence of asset sell-off in the bond market[1] - Federal Reserve Governor Waller suggested that if tariffs are below 10%, the Fed may be more patient with interest rate cuts, potentially occurring in the second half of the year[2] Commodity and Financial Market Performance - Domestic commodity futures showed mixed results, with energy and chemical products mostly declining, while crude oil rose by 1%[2] - NYMEX crude oil closed at $77.13, down 14.17% year-to-date, while COMEX gold increased by 22.18% year-to-date, closing at $3226.80[3] - The Shanghai Composite Index closed at 3262.81, down 2.65% year-to-date, while the Dow Jones Industrial Average rose by 0.78% on the day[3]

4月3日凌晨特朗普宣布了新一轮"对等关税"政策，对中国大陆实际关税税率抬升至5 4%，略高于 此前市场的预期，而对等关税受影响较大的主要集中在欧盟（2 0%）、越南（4 6%）、中国台湾 （3 2%）、日本、韩国、泰国印尼马来西亚等东南亚国家和地区，不过保留了一定的谈判空间。我 们认为特朗普展示的（美方视角下）双边关税差异可能是美国关税政策加征的阶段性"终点"，不过 最终执行结果或弱于口头沟通，市场实质性的恐慌情绪一次性到位，后续应重点关注政策落地及执 行以及新政策的出台。而对华关税方面，后续应特别注意观察中美关系从当前的"制裁-反制 裁"向"管控分歧-防风险"方向的变化，在不确定性情绪积聚以及释放以前，该因素对资产价格的影 响尚未结束。 ▍ 事件： 文 ｜ 贾天楚 崔嵘 李翀 韦昕澄 北京时间2 0 2 5年4月3日凌晨，据新华社消息，美国总统特朗普在白宫签署两项关于所谓"对等关 税"的行政令，宣布美国对贸易伙伴设立1 0%的"最低基准关税"，并对某些贸易伙伴征收更高关 税。对此我们点评如下： ▍ 关税具体内容： 1）对华关税方面：白宫表示对中国大陆征收的关税是在现有 2 0%关税的基础上征收的，这意味 着 ...